- Researchers have
identified a 17 gene signature which can be used to calculate Leukemia Stem Cell 17 (LSC17)score which
determines if chemotherapy will be an effective
- Leukemia stem cells cannot be treated with
chemotherapy or radiation due to the microenvironment in the bone marrow.
- Nanostring is a digital platform that can be used to calculate the stemness score which will aid the physician as it is ain predictive and prognostic biomarker for acute myeloid leukemia treatment.
A 17 gene
signature has been identified by the research team from the Princess Margaret Centre
from stem cells that can be used to diagnose whether patients suffering from acute myeloid
will respond to
Dr. Jean Wang
who is the Affiliate Scientist at the Princess Margaret, University Health
Network (UHN) said that the gene signatures could be used as a risk assessment
tool to determine the individual response and the course of treatment that
would suit treatment.
‘LSC 17 can be a predictive and prognostic biomarker for treatment of AML.’
medicine is growing in popularity and tests are being developed to assess
personal response to treatment and medications. Such gene marker tests are
routinely used to determine the need for intensive therapies like chemotherapy
tests determine the recurrence risk for cancer and if the recurrence risk is
low, then chemotherapy may not be advised.
- Doctors will get a better
understanding about the type of cancer.
- The recurrence risk
of cancer can be determined.
- It will identify response to
biomarker LSC17 score has the following factors
- This biomarker is derived from
leukemia stem cells that are responsible for driving
- Chemotherapy is resisted by these dormant
- This is the underlying factor for return in cancer
of using the LSC17 score is that patients who are found to be resistant to the
standard form of chemotherapy will easily be identified by physicians. This
will aid in
Cancer Cells in Acute Myeloid
- Avoiding side effects and trauma
incurred due to chemotherapy.
- It will avoid wasting time
and resources on standard chemotherapy measures.
adaptive techniques that are novel or post remission therapies can be used for
such patients to control the growth of cancer.
leukemia was one of the first diseases in which it was determined
that the disease was sustained by leukemia stem cells. This was identified when
it was found that not all leukemia cells had the ability to proliferate indefinitely,
which was determined by growing the leukemia cells in- vitro
. Only a small fraction of cells was found to grow in
Leukemia stem cells that
give rise to AML were evaluated by isolating these cells and injecting them
into immune-deficient mice which helped in identifying that these cells
resulted in the development of cancer.
In AML, the
leukemic blasts that rapidly divide are eliminated by
chemotherapeutics but the leukemia stem cells are resistant to chemotherapy and
radiation, due to the microenvironment of the bone marrow. They remain in the
body and there is regrowth of the cancer cells, resulting in a very short period
The LSC17 score was
determined by studying the leukemia samples from 78 acute myeloid leukemia
patients along with their gene expression patterns. The researchers in the
study then determined the stemness score using statistical methods.
Stanley W. K. Ng, who is
the co-author of the study said 㜁e identified the minimal set of genes that
were most critical for predicting survival in these other groups of AML patients,
regardless of where they were treated. With this core 17-gene score, we have
shown we can rapidly measure risk in newly diagnosed AML patients,"
of the Score
would respond well to chemotherapy and there is a low chance of remission.
not respond well to stand forms of therapy even after a stem cell
The method of
determining the score has been converted into a platform called Nanostring that
will aid in quicker turn around. This will aid the score from being used widely
in the clinical set up.
Dr. Wang further added
"The LSC17 score is the most powerful predictive and prognostic biomarker
currently available for AML, and is the first stem cell-based biomarker
developed in this way for any human cancer. Clinicians will now have a tool
that they can use upfront to tailor treatment to risk in AML."
This type of cancer is
characterized by the production of abnormal myelocytes in the bone marrow, red
blood cells or platelets. The initial symptoms associated with the condition
include fever, easy bruising, feeling of being tired and bleeding. This cancer
should be detected early as it increases in intensity very fast.
The pathogenesis of this
type of cancer is due to the over production of white blood cells in the bone
marrow which result in poor numbers of red blood cells and platelets. As the
number of these immature cells increase, they begin to circulate in the blood
and since they are immature, they cannot perform their functions well. This
lowers their immunity and it can lead to poor defense against infection.
The current study will
aid in identifying the line of treatment that will be effective and the
prognosis of the patient.
- Acute myeloid leukaemia (AML) - (https://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq)
- General Information About Adult Acute Myeloid
Leukemia - (http://www.leukaemia.org.au/blood-cancers/leukaemias/acute-myeloid-leukaemia-aml)